Background: Prostacyclin mimetics are vasodilatory agents used in the treatment of pulmonary arterial hypertension. The direct effects of prostanoids on right-ventricular (RV) function are unknown. We aimed to investigate the direct effects of prostacyclin mimetics on RV function in hearts with and without RV hypertrophy and failure.
INTRODUCTION
Prostacyclins have since the 80s been a cornerstone in the treatment of pulmonary arterial hypertension (PAH) owing to effective vasodilatory, antiproliferative, and antithrombotic properties. [1] [2] [3] Despite optimal drug therapy, PAH remains a devastating disease leading to impaired quality of life and premature death. 4 Although PAH originates in the pulmonary vasculature, prognosis is closely associated with progression of right-ventricular (RV) dysfunction and failure. The right ventricle suffers from sustained pressure overload, leading to hypertrophy, fibrosis, and ultimately dilatation and failure, leaving RV failure the most common cause of death in patients with PAH. 5, 6 The inotropic effects of prostacyclin analogues in the right ventricle have only been investigated in a few previous studies. [7] [8] [9] [10] [11] Kemming et al 11 reported increased RV contractility in healthy pigs when subjected to epoprostenol and iloprost inhalation, whereas others have investigated them in several different models for RV failure. 7, 9, 10, 12 However, models with unfixed afterload make it difficult to separate direct effects on the heart from those resulting in changes in the systemic and pulmonary circulation.
Although prostacyclins are potent activators of the prostaglandin I2 (IP) receptor, they will to varying degrees activate other prostanoid receptors. 13 This prompted the development of the IP receptor-specific drug, selexipag. 14 The 8 G-protein-coupled prostanoid receptor subtypes work through different subcellular pathways (Gs, Gi, and Gq). They are divided into subfamilies based on their ability to relax or contract smooth muscle. 13, 15 The prostacyclin analogues, used in the treatment of PAH, have diverse affinity and selectivity for the receptor subtypes. 16, 17 The distribution and function of these different receptor subtypes in the pulmonary vasculature have been investigated in recent years. 16, 18, 19 The distribution in the right ventricle and its influence on the effect of the prostacyclins on the right heart remains, however, to be characterized.
In the present study, we investigated the direct effects of iloprost, treprostinil, epoprostenol, and MRE-269, the metabolite from selexipag, on RV function in the normal right ventricle and in a model of pressure overload-induced RV hypertrophy and failure. Choosing the isolated perfused heart model not only allowed us to test a wide dose range but also excluded potential influence from the pulmonary and systemic circulation. We also investigated the role of the different prostanoid receptors in the right ventricle to help further characterize the myocardial action of prostacyclin mimetics.
METHODS
Outbred, male, Wistar rats were used in the experiments (n = 149). The rats were housed in pairs, allowed free access to water and standard rat chow, and subjected to a 12-hour lightdark cycle. All experiments were performed in concordance with the Guide for the Care and Use of Laboratory Animals (NIH, 2011) 20 and were approved by the Danish Animal Experiments Inspectorate (Authorization number: 2012-15-2934-00384). Method details are provided in the Supplemental Digital Content (http://links.lww.com/JCVP/A242).
Rat Model of RV Hypertrophy and Failure
Anesthesia was induced with 7% sevoflurane and maintained with 3.5% sevoflurane in a mixture of O 2 1 L/min and N 2 O 0.5 L/min. To reduce postoperative pain, buprenorphine was injected subcutaneously (0.12 mg/kg) during the procedure and applied to the drinking water (7.4 mg/mL) for 3 days postoperatively.
RV hypertrophy and failure were induced by pulmonary trunk banding (PTB) as previously described. 8, 21 The banding clip was applied in rats (90 6 5 g) and compressed to an inner diameter of 1.0 mm (n = 32) or 0.5 mm (n = 32). The rats were left for 7 weeks generating either RV hypertrophy (HYP) or manifest RV failure (FAIL). Rats without banding served as healthy controls (CON).
Echocardiography
Before isolating the hearts, RV hypertrophy and function were evaluated using a Vevo 2100 echocardiographic system (Visual Sonics, Toronto, Canada) with a 21-MHz linear array transducer. All analyses were made during expiration and are presented as the mean of 3 consecutive measurements.
The Isolated Perfused Heart ModelLangendorff
Anesthesia was induced with a subcutaneous injection of a mix of midazolam, fentanyl citrate, and fluanisone. The aorta was cannulated, and retrograde perfusion was initiated before cutting out the heart. It was connected to a pressurecontrolled Langendorff system as previously described. 22 Krebs-Henseleit buffer was used as perfusion media and gassed with 95% O 2 and 5% CO 2 to keep the pH at 7.4, and the heart was oxygenated.
RV hemodynamic parameters were monitored using a fluid-filled balloon introduced into the right ventricle and connected to a pressure transducer.
Coronary flow rate was measured using an in-line flow probe as an integrated part of the modified Langendorff setup (Type 2.5SB; Transonic System Inc, Ithaca, NY). Coronary flow reserve (CFR) was estimated as CFR = CF max /CF baseline after coronary flow was normalized to the weight of the heart, where CF max denotes the maximum flow reached with prostacyclin mimetic administration and CF baseline denotes the coronary flow at baseline.
Study Design Effects of Prostacyclins on RV Function
Control (n = 30), hypertrophic (n = 32), and failing hearts (n = 32) were mounted in the Langendorff system, and after 20-30 minutes of stabilization, each heart was perfused with iloprost (0.02-6 ng/mL), treprostinil (0.5-150 ng/mL), epoprostenol (0.06-20 ng/mL), or MRE-269 (30-10,000 ng/mL). The hearts were perfused with each concentration for 10 minutes followed by 5 minutes perfusion of dobutamine (0.1 mg/mL) to test the contractile reserve of each isolated heart. Iloprost, treprostinil, epoprostenol, and selexipag are all clinically available agents used in the treatment of PAH. MRE-269, the active metabolite of selexipag, is approved only for experimental use.
Coronary Artery Dilatation and RV Function
A potential association between coronary artery dilatation and RV function was investigated in additional 2 sets of experiments. One set of healthy hearts (n = 7) was subjected to treprostinil perfusion as described above, while keeping the flow constant at 13 mL/min throughout the experiment. As the hearts were perfused with increasing concentrations of treprostinil, causing a gradual coronary vasodilation, the perfusion pressure was manually decreased keeping the coronary flow at 13 mL/min. At the end of the protocol, the hearts were perfused with a dose of dobutamine to verify the ability to induce an inotropic response despite a constant coronary flow and a decreasing perfusion pressure.
Another set of healthy (n = 8), hypertrophic (n = 8), and failing (n = 8) rat hearts were perfused with the vasodilator, sodium nitroprusside (Nitropress; Hospira, Inc, Lake Forest, IL) (0.125-0.5 mg/mL), to investigate the effect of coronary vasodilation by a pure vasodilator on RV function.
Expression of Prostanoid Receptors in the Right Ventricle
RV tissue excised from healthy hearts (n = 8), hearts with RV hypertrophy (n = 8), and hearts with RV failure (n = 8) was snapped frozen in liquid nitrogen, and cDNA was synthesized from RNA isolated from the RV tissue. Primers used in quantitative polymerase chain reaction (qPCR) were designed for the b-myosin heavy chain (b-MHC); sarco/endoplasmatic reticulum Ca 2+ -ATPase 2 (SERCA-2); and the rat prostanoid receptors IP, EP 1 , EP 2 , EP 3 , EP 4 , DP 1 , TP, and FP genes (see Table  s1 , Supplemental Digital Content, http://links.lww.com/ JCVP/A243). The level of mRNA was normalized to the reference gene, glyceraldehyde 3-phosphate dehydrogenase.
Prostanoid Receptors and RV Function
In a subset of experiments, healthy rat hearts were perfused with increasing concentrations of treprostinil (0.5-150 ng/mL) together with commercially available antagonists for the DP 1 (n = 8), EP 2 (n = 8), or IP receptor (n = 8). The aim was to investigate the influence of each receptor subtype on the effect of treprostinil in the right ventricle. After stabilization, the hearts were perfused with the antagonist alone for 10 minutes, followed by increasing concentrations of treprostinil. The concentration of the receptor antagonist was kept constant during treprostinil perfusion.
Statistics
Unless otherwise stated, normally distributed data are presented as means 6 SD. Data were tested for normal distribution using normality test. Significance of difference was evaluated using 1-way analysis of variance (ANOVA) for repeated measurements followed by a relevant multiple comparisons test, 2-way ANOVA or Student's t test.
Observations not normally distributed were tested with equivalent nonparametric tests. The P value of ,0.05 was considered to represent statistical significance. All data were analyzed using GraphPad Prism (version 6.0; GraphPad Software, Inc, San Diego, CA).
RESULTS

RV Hypertrophy and Failure
Banding resulted in pressure overload to the right ventricle, demonstrated by more than a 2-fold increase in baseline RV-developed pressure (RVDP) compared with control hearts (Fig. 1A) . Progression of RV hypertrophy was related to the severity of PTB, shown by an increased right ventricle weight/tibia length in the HYP group, with an even further increase in the FAIL group (Fig. 1B) . Tricuspid annular plane systolic excursion (TAPSE) was decreased in Results are presented as mean 6 95% confidence interval relative to mRNA level of controls, normalized to 1. ****P , 0.0001, the HYP group compared with the control group and in the FAIL group compared with both controls and HYP (CON vs. HYP, mm: 2.0 6 0.15 vs. 1.5 6 0.17, P , 0.0001, CON vs. FAIL: 2.0 6 0.15 vs. 1.1 6 0.16, P , 0.0001, HYP vs. FAIL: 1.5 6 0.17 vs. 1.1 6 0.16, P , 0.0001, 1-way ANOVA) (Fig. 1C) .
Cardiac output was preserved in the HYP group, contrary to the FAIL group, which had a significantly lower cardiac output compared with both the control group and the HYP group (Fig. 1D) .
To assess the effect of PTB on genes related to hypertrophy and heart failure, we determined the expression of b-MHC and SERCA-2 mRNA in the right ventricle. Analysis revealed upregulation of b-MHC in the failing right ventricle and a downregulation of SERCA-2 in the hypertrophic and failing right ventricle compared with controls (Figs. 1E,  F) . Furthermore, almost half of the rats in the FAIL group presented with clinical manifestations of severe RV failure (Table 1) .
Contractile Reserve of the Right Ventricle
To assess the contractile reserve of the right ventricle, all hearts were perfused with dobutamine at the end of the protocol. Dobutamine elevated heart rate in all 3 groups (see 
Coronary Flow Reserve
When normalized to the weight of the heart, CFR was reduced in the hypertrophic hearts and even lower in the failing hearts, compared with controls (CON vs. HYP: 1.9 6 0.6 vs. 1.5 6 0.3, P , 0.05, CON vs. FAIL: 1.9 6 0.6 vs. 1.2 6 0.2, P , 0.0001, HYP vs. FAIL: 1.5 6 0.3 vs. 1.2 6 0.2, P , 0.01, 1-way ANOVA). There was no difference in baseline coronary flow between the groups when normalized to the heart weight.
Effects of Iloprost on RV Function
Iloprost increased coronary flow in all 3 groups of isolated hearts (CON: P , 0.0001, HYP: P = 0.0001, FAIL: P = 0.0032, 1-way ANOVA). The increase was, however, less pronounced in the HYP group and even lower in the FAIL group ( Fig. 2A) .
Iloprost improved RV function in the control hearts, demonstrated by an increase in RVDP, dP/dtmax, and rate pressure product (RPP) (P = 0.046, P = 0.035, and P = 0.015, respectively, 1-way ANOVA).
Iloprost did not alter RV function either in the HYP group or in the FAIL group, though we observed a trend toward a reduction in RVDP (P = 0.061, 1-way ANOVA) (Figs. 2B-D) .
Iloprost did not alter heart rate in any of the groups. 
Effects of Treprostinil on RV Function
Perfusion with increasing concentrations of treprostinil increased coronary flow in the control hearts. The increase was lower in hearts with hypertrophic and failing right ventricle (CON: P , 0.0001, HYP: P = 0.0008, FAIL: P = 0.017, 1-way ANOVA) (Fig. 3A) .
In the controls, treprostinil improved RV function, increasing RVDP, dP/dtmin, and RPP (P = 0.045, P = 0.01, and P = 0.002, respectively, 1-way ANOVA). The effect was mainly evident for the 2 lowest concentrations, comparable with doses used in the clinic. Higher concentrations blunted the response.
Treprostinil had a small, nonsignificant positive effect on RV function in the HYP group when administered in the lowest concentration. Increasing concentrations reduced RVDP, dP/dtmax, and RPP below the baseline value (P = 0.005, P = 0.03, and P = 0.005, respectively, 1-way ANOVA).
In the failing right ventricle, treprostinil impaired RV function by reducing RVDP (P = 0.002, 1-way ANOVA) (Figs. 3B-D) . Treprostinil elevated heart rate in the failing right ventricle (P = 0.034, 1-way ANOVA), but heart rate was unaltered in the controls and the hypertrophic hearts.
Effects of Epoprostenol on RV Function
Epoprostenol elevated coronary flow in all hearts (CON: P , 0.0001, HYP: P = 0.0009, FAIL: P , 0.0001, 1-way ANOVA). The increase was lower in the HYP group and lowest in the FAIL group (Fig. 4A) .
Epoprostenol improved RVDP (P = 0.13) and dP/ dtmax (P = 0.06) in the control group (Figs. 4B-D) ; however, it did not reach statistical significance. There was no effect of epoprostenol on the hypertrophic and failing hearts.
Epoprostenol did not alter heart rate in any of the groups. 
Effects of MRE-269 on RV Function
In controls and to a lesser extent in hypertrophic hearts, MRE-269 increased coronary flow rate. The increase in the FAIL group was nonsignificant (CON: P , 0.0001, HYP: P = 0.0009, FAIL: P = 0.074, 1-way ANOVA) (Fig. 5A) .
Perfusion with MRE-269 improved RV performance in the control hearts measured by dP/dtmax, RPP, and RVDP (P = 0.003, P = 0.035, and P = 0.085, respectively, 1-way ANOVA). In the HYP and the FAIL groups, MRE-269 impaired RV function markedly, when administered in supraclinical concentrations (RVDP HYP: P , 0.0001, RVDP FAIL: P , 0.0001, 1-way ANOVA) (Figs. 5B-D) .
MRE-269 did not alter heart rate in any of the groups.
Coronary Artery Dilatation and RV Function
Treprostinil perfusion of control hearts, while keeping coronary flow constant, caused a decrease in RVDP, dP/dtmax, and RPP (P = 0.006, P = 0.01, and P = 0.006, respectively, 1-way ANOVA). Perfusion with dobutamine, however, increased RVDP, dP/dtmax, and RPP (see Figure s2 , Supplemental Digital Content, http://links.lww.com/JCVP/A245).
Perfusion of control and hypertrophic hearts in the pressure-controlled setup with the vasodilator, sodium nitroprusside, increased coronary flow rate (CON: P = 0.001, HYP: P , 0.0001), RVDP (CON: P = 0.006, HYP: P , 0.0001), and dP/ dtmax (CON: P = 0.024, HYP: P , 0.0001). In the failing hearts, however, the increase in coronary flow was less pronounced and there was no effect on RVDP (FAIL: P = 0.87) and dP/dtmax (FAIL: P = 0.56) in this group (see Figure s3 , Supplemental Digital Content, http://links.lww.com/JCVP/A246).
Prostanoid Receptors in the Right Ventricle
mRNA expression analysis revealed that all 8 prostanoid receptor subtypes were expressed in the right ventricle from controls. In the hypertrophic right ventricle, there was an elevated expression of the EP 1 , EP 3 , EP 4 , IP, and TP receptor and a reduced expression of the DP 1 receptor. In the failing right ventricle, the expression of the EP 2 , EP 3 , and IP receptor was elevated, whereas the expression of EP 4 and DP 1 was reduced. Expression of the EP 1 and TP receptor was not significantly altered (Fig. 6) .
Perfusion with the IP receptor antagonist, RO1138452, effectively inhibited the effect of treprostinil on coronary flow. It resulted in a rightward shift of the concentrationresponse curve when RO1138452 was added to the perfusion media (Fig. 7A) . The effect on RV function was also antagonized by RO1138452, causing a reduction in RVDP (Fig. 7B) . Perfusion with the DP 1 receptor antagonist, BW A868C, and the EP 2 receptor antagonist, PF04418948, failed to alter the effect of treprostinil (see Figure s4 , Supplemental Digital Content, http://links.lww.com/JCVP/A247).
DISCUSSION
This study is to our knowledge the first to investigate and compare the direct effects of 4 prostacyclin mimetics on RV function in a well-established model of RV hypertrophy and failure. The drugs tested are used clinically for the treatment of PAH. We found that administration of iloprost, treprostinil, and MRE-269 improved RV function in healthy control hearts. This effect, however, was absent in hearts with RV hypertrophy and in hearts with manifest RV failure. Treprostinil and MRE-269 even impaired RV function in hearts with RV failure.
RV Hypertrophy and Failure
With PTB, we created 2 groups of rats: 1 with RV hypertrophy and 1 with manifest RV hypertrophy and failure. Rats subjected to the severe banding developed RV hypertrophy and manifest failure, demonstrated by a major increase in RV pressures and RV weight, a reduction in TAPSE and cardiac output, and altered expression of genes related to hypertrophy and failure. 23, 24 These findings are comparable with both animals and humans with decompensated RV hypertrophy and failure. 5, 21, 25, 26 Rats subjected to the mild banding presented with elevated RV pressures, increased RV weight, and reduced TAPSE but preserved cardiac output. This agrees with previous studies 25, 27 and suggests an adaptive remodeling of the right ventricle with preserved systolic function.
Using this well-established method, we were able to separate the rats into 3 distinct groups. It allowed us to investigate and compare the effects of prostacyclin mimetics in the healthy right ventricle and in the hypertrophic and the failing right ventricle.
Effects of Iloprost, Treprostinil, Epoprostenol, and MRE-269 on RV Function
In healthy control hearts, all 4 agents doubled the coronary flow. Iloprost, treprostinil, and MRE-269 improved RV function; however, only treprostinil was effective in concentrations comparable with those used for PAH patients. The effect of epoprostenol did not reach statistical significance, which agrees with previous studies, showing a tendency toward epoprostenol being less effective than iloprost at increasing contractility. 11, 28 The differences observed among the agents may be related to their heterogeneous affinity and activity at the prostanoid receptors. Iloprost has a high affinity for the EP 1 and IP receptor, whereas treprostinil has a high affinity for DP 1 and EP 2 receptors, though slightly less at the IP receptor. 16, 29 In this study, we were able to abolish the effect of treprostinil on RV function with a selective IP receptor antagonist, suggesting that the IP receptor plays a role in mediating the function of the right ventricle. Previous studies have suggested an antihypertrophic effect of the IP receptor in the heart, 30,31 which may explain the major upregulation of this receptor in the hypertrophic right ventricle, but a role in RV function has to our knowledge not been demonstrated until now. Given the IP receptor plays a role in RV function, one might think that the selective IP receptor agonist, MRE-269, would be the more potent agent. However, recent data suggest that MRE-269 may affect a nontypical IP receptor and/or is not completely selective to the IP receptor in rats. 19 In the hearts with hypertrophic right ventricle, we found no effect of iloprost, treprostinil, and epoprostenol, whereas MRE-269 had a small negative effect on RV function. In hearts with manifest RV failure, the negative effect of MRE-269 was more pronounced and also treprostinil had a small negative effect on RV function. It suggests that the effect of the prostacyclin mimetics is dependent on the degree of RV hypertrophy and failure. This agrees with the study of Riise and collegues, who reported prostanoidmediated inotropic responses to be attenuated in the failing human myocardium. 32 The negative effect observed in this study was, however, only observed with high supraclinical doses.
Reduced contractile reserve of the right ventricle may influence the effect of the prostacyclin mimetics in hearts with RV hypertrophy and failure. Decreased contractile reserve is associated with a low response to pharmacological therapy in heart failure. 33, 34 We tested the contractile reserve of the right ventricle by perfusion with dobutamine. The contractile reserve of the right ventricle was preserved in the hypertrophic group despite high baseline RV pressures. In the failing right ventricle, the contractile reserve was on the other hand reduced. The increase in dP/dtmax was less pronounced, and surprisingly, dobutamine decreased RVDP, indicating that the right ventricle was at the limit of its performance. The b1 adrenoceptors have previously been shown to be downregulated in the process of heart failure 35 and may result in the reduced contractile reserve and response to dobutamine perfusion in the hearts with manifest RV failure.
Reduced contractile reserve may partly explain the absent effect of the prostacyclin mimetics in the failing right ventricle. This, however, does not explain the attenuated effect in the hypertrophic right ventricle, where contractile reserve was preserved. The altered response in the hypertrophic and failing right ventricle could be related to the altered prostanoid receptor expression. The prostanoid receptors cross-react at the second messenger pathway level, and a change in composition of the receptors in the right ventricle may alter the interaction between the receptor subtypes. 15, 29 We observed an increased expression of the EP 3 receptor in the hypertrophic right ventricle and the receptor was even more upregulated in the failing right ventricle. The EP 3 expression increased 3-fold compared with a 1.9-fold increase in IP receptor expression in the failing right ventricle. It has recently been shown that the EP 3 receptor is a negative modulator of the IP receptor, 36 and all prostacyclins will activate these receptors, with epoprostenol the most likely at clinical doses. 13 Negative modulation of the IP receptor from the EP 3 receptor may become more dominant in the failing right ventricle contributing to an altered effect of the prostacyclin mimetics in the right ventricle. Indeed, EP 3 receptors reduce the inotropy of beta-adrenergic stimulation in pigs, which may be an antiischemic mechanism in the heart. 37 We found an increased expression of the EP 4 receptor in the HYP group, but a decreased expression in the FAIL group. The EP 4 receptor has previously demonstrated involvement in cardiac hypertrophy 38, 39 and may explain its upregulation in the adaptive and hypertrophic response in the HYP group and its downregulation in the failing, dilating, and ischemic right ventricle.
The expression of prostanoid receptors was evaluated by qPCR. A limitation of qPCR is that it measures mRNA levels, not protein levels. It will thus merely suggest changes in the level of protein and function than actually demonstrate it. 40 The demonstration of the presence and level of the receptor protein were in this study limited by the lack of available specific antibodies.
The prostacyclins are known for their vasodilatory effects, and in this study, we were also able to demonstrate a marked increase in coronary flow, reflecting vasodilation of FIGURE 6. Expression of mRNA for the prostanoid receptor subtypes in the right ventricle, quantified by PCR. The data were normalized to the reference gene, glyceraldehyde 3-phosphate dehydrogenase. Control, n = 8; hypertrophic, n = 8; failure, n = 8. Results are presented as mean 6 95% confidence interval relative to the mRNA level of the controls,the coronary arteries. As the increase in contractility in the control hearts was accompanied by a simultaneous increase in coronary flow, we hypothesized that the mechanism of action of the prostacyclin mimetics on RV function is, at least partly, related to vasodilatation of the coronary arteries. To investigate this, we compared the effect of treprostinil on RV function under constant flow and found that the positive effect of treprostinil on RV contractility was absent. This suggests that treprostinil works at least mainly via coronary artery dilation to increase contractility of the right ventricle rather than a direct inotropic effect on the cardiomyocytes. This could be explained by increased coronary microvascular filling and thus stretch of the sarcomeres and/or release of positive inotropic factors, leading to increased contractility. [41] [42] [43] Also the nitroprusside experiments support the theory that coronary vasodilation could improve RV function. We found that nitroprusside, which can be considered a "pure" vasodilator, improved RV contractility in the control hearts and the hypertrophic hearts where the coronary flow was increased. This is in agreement with previous findings. 44 In the failing hearts, where the increase in coronary flow was low, there was no effect on RV contractility. Further studies are, however, needed to fully confirm this mechanism. In contrast to the prostacyclin mimetics, dobutamine was able to increase RV contractility in the constant flow setup. This also indicates that the prostacyclin mimetics work through a different mechanism than the cardiac inotrope, dobutamine.
We found no difference in baseline coronary flow among the experimental groups. The response to prostacyclin administration was, however, attenuated in the hypertrophic and failing hearts, representing a reduced CFR at the more advanced stage of RV hypertrophy and failure. CFR has shown to be decreased in PAH patients and correlated to the degree of RV dysfunction. 45, 46 Decreased cardiomyocyte/ fibrosis ratio, reduced capillary density in the myocardium, and increased diastolic stiffness are known characteristics of our PTB model. 21 Given that the prostacyclin mimetics are dependent on increase in coronary flow to improve RV function, reduced CFR, microvascular dysfunction, reduced capillary density, and increased fibrosis may contribute to the attenuated effect of the prostacyclin mimetics on RV function in hearts with RV hypertrophy and failure.
To develop targeted treatments for patients with PAH and RV failure, it is necessary to fully characterize the effect of prostacyclin mimetics on RV function. The current study represents another step on this journey, though further studies delving deeper into the mechanism of action are needed.
Limitations
The study was carried out in rat hearts in an ex vivo experimental setup. Data from rat tissue may not be directly transferable to human tissue, and pharmacologic effects may be different in the intact animal. This should be taken into consideration before clinical translation of the results.
The banding of the rats was applied on preadolescent rats (approximately 90 g) to secure slow and gradually development of RV hypertrophy and failure. Initiation of disease development in preadolescents, however, does not apply to the majority of the clinical cases of RV failure. Though it is unlikely to play a major role because the evaluation was performed in the fully grown rats, this should be taken into consideration when interpreting the results. 
